Omarigliptin

Source high-purity Omarigliptin, a potent, long-acting DPP-4 inhibitor designed for the once-weekly management of type 2 diabetes. This advanced pharmaceutical intermediate offers superior stability and patient compliance benefits, making it an ideal choice for manufacturers developing next-generation antidiabetic formulations. Secure reliable supply for your R&D and production needs. High-quality raw material. Get a quote today!

Product Specification

• Product Name: Omarigliptin (Pharmaceutical Grade)
• Appearance: White to off-white crystalline powder
• CAS No.: 1252909-37-0
• Molecular Formula: C₁₆H₁₅F₃N₆O
• Specification: Purity ≥98.5% (HPLC); Molecular Weight: 368.32 g/mol; Loss on Drying: <0.5%; Residual Solvents: Compliant with ICH Q3C guidelines; Single Impurity: <0.1%
• Ingredient Information: Synthetic small molecule; Slightly soluble in water, soluble in organic solvents like methanol and DMSO; Long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor

Product Description

Omarigliptin is a novel, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor distinguished by its exceptional pharmacokinetic profile, allowing for once-weekly dosing. Unlike daily DPP-4 inhibitors, Omarigliptin forms a strong, long-lasting bond with the DPP-4 enzyme, providing sustained inhibition that effectively regulates blood glucose levels by enhancing incretin activity. Its unique structure ensures high selectivity and minimal risk of hypoglycemia when used as monotherapy or in combination with other antidiabetic agents. The convenience of weekly administration significantly improves patient adherence, positioning Omarigliptin as a competitive candidate in the global market for chronic diabetes management. It represents a significant advancement in therapeutic convenience without compromising efficacy or safety.

Product Uses

This ingredient is primarily utilized in the pharmaceutical industry for the development of oral solid dosage forms, such as tablets and capsules, intended for the treatment of type 2 diabetes mellitus. It serves as the key active pharmaceutical ingredient (API) in formulations aimed at improving glycemic control in adults. Additionally, Omarigliptin is extensively used in preclinical and clinical research to study DPP-4 inhibition mechanisms, glucose metabolism, and beta-cell function. It is also explored in combination therapies alongside metformin or insulin to evaluate synergistic effects on blood sugar regulation. Due to its specific regulatory status, its application is strictly confined to prescription drug manufacturing and biomedical research contexts.

Formulation Recommendation

Recommended Usage Level: Typical therapeutic dosage equivalents range from 25 mg once weekly. For formulation development, active content should be adjusted based on bioavailability studies and target release profiles.
Addition Method: Due to limited water solubility, Omarigliptin is best processed using wet granulation or direct compression methods with suitable fillers. Micronization may be required to enhance dissolution rates. Incorporate uniformly into the blend with excipients such as microcrystalline cellulose, lactose, and magnesium stearate.
Compatibility: Compatible with common tablet excipients including binders, disintegrants, and lubricants. Stable under standard storage conditions but should be protected from excessive moisture and light. Avoid strong acidic or basic environments during processing to prevent degradation. Synergizes well with metformin hydrochloride in fixed-dose combination formulations, requiring careful pH management to ensure stability of both actives.